Compare NUVB & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVB | LGIH |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.3B |
| IPO Year | 2020 | 2013 |
| Metric | NUVB | LGIH |
|---|---|---|
| Price | $4.50 | $42.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 5.0M | 350.7K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.56 | N/A |
| EPS | N/A | ★ 1.25 |
| Revenue | $62,902,000.00 | ★ $1,705,504,000.00 |
| Revenue This Year | $209.36 | $6.07 |
| Revenue Next Year | $41.60 | $11.62 |
| P/E Ratio | ★ N/A | $34.17 |
| Revenue Growth | ★ 698.96 | N/A |
| 52 Week Low | $3.92 | $33.55 |
| 52 Week High | $9.75 | $66.25 |
| Indicator | NUVB | LGIH |
|---|---|---|
| Relative Strength Index (RSI) | 31.70 | 41.71 |
| Support Level | $4.45 | $39.35 |
| Resistance Level | $5.16 | $51.77 |
| Average True Range (ATR) | 0.24 | 2.27 |
| MACD | 0.02 | 0.18 |
| Stochastic Oscillator | 16.78 | 52.78 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.